Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Trial details
- Registry ID
- NCT06641414
- Drugs studied
- Azacitidine Injection, Lisaftoclax (APG-2575)
TrialRedline tracks 10 clinical trials sponsored by Ascentage Pharma Group Inc.: 7 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLNCT05147467 | APG2575 | Recruiting | 2026-12Estimated |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLNCT04496349 | APG-115, APG-2575 | Recruiting | 2026-05-31Estimated |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseNCT04126681 | HQP1351, Homoharringtonine, Hydroxyurea or Interferon-based therapy, Imatinib, Dasatinib or Nilotinib | Completed | 2024-08-01Actual |
Names as written in the registry records.
NCT06423911 · Ascentage Pharma Group Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: MMR rate Part A Measure: MMR rate Part B. After: Measure: 24-Week MMR Rate (Part A) Measure: 24-Week MMR Rate (Part B).
Before: 285 participants (planned). After: 333 participants (planned).
Before: Dec 2025. After: 30 Jun 2027.
NCT06104566 · Ascentage Pharma Group Inc.
Before: 20 Oct 2025. After: 31 Dec 2026.
NCT06051409 · Ascentage Pharma Group Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Minimal residual disease negativity rate. After: Measure: Minimal Residual Disease Negative CR Rate.
Before: 31 Dec 2024. After: 31 Dec 2027.
NCT05147467 · Ascentage Pharma Group Inc.
Before: Sep 2024. After: Dec 2026.